FGFR Gene Alteration clinical trials at UCSD
2 in progress, 1 open to eligible people
Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
open to eligible people ages 18 years and up
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.
La Jolla, California and other locations
KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-3248, an oral small molecule FGFR inhibitor, in adults with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations.
La Jolla, California and other locations
Our lead scientists for FGFR Gene Alteration research studies include Burgoyne Adam.
Last updated: